Mesa Laboratories Q2 revenue rises on divisional performance
MLAB•Mesa Laboratories' fiscal second-quarter revenue rose 2.6% year over year to $62.34 million, while net income climbed 75% to $4.34 million and EPS was $0.75. The company authorized a new $40 million share repurchase program and expects fiscal 2027 revenue of $250 million to $255 million.
1. Quarterly results
Mesa Laboratories reported fiscal second-quarter revenue of $62.34 million, up 2.6% year over year and slightly above the $62.20 million consensus estimate. Net income rose 75% to $4.34 million, and EPS was $0.75.
2. Divisional performance
Revenue growth was led by Sterilization and Disinfection Control and Calibration Solutions, while Biopharmaceutical Development declined. Resolved production issues supported higher shipments in Sterilization and Disinfection Control; export-control processing delays weighed on peptide hardware sales in Biopharmaceutical Development.
3. Outlook and repurchases
Mesa Laboratories authorized a new $40 million share repurchase program. It expects fiscal 2027 revenue of $250 million to $255 million and adjusted EBITDA of $66 million to $68 million, while third-quarter revenue is expected to be flat year over year, mainly due to lower Clinical Genomics.
